Ro 6-3129

Ro 6-3129
Clinical data
Other names16α-Ethylthiodydrogesterone; 16α-Ethylthio-6-dehydroretroprogesterone; 16α-Ethylthio-9β,10α-pregna-4,6-diene-3,20-dione
Routes of
administration		Oral
Identifiers
  • (1R,2S,10S,11S,13R,14S,15S)-14-Acetyl-13-(ethylsulfanyl)-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-6,8-dien-5-one
CAS Number
ChemSpider
Chemical and physical data
FormulaC23H32O2S
Molar mass372.57 g·mol−1
3D model (JSmol)
  • CCS[C@@H]1C[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]2(C)[C@H]1C(C)=O
  • InChI=1S/C23H32O2S/c1-5-26-20-13-19-17-7-6-15-12-16(25)8-10-22(15,3)18(17)9-11-23(19,4)21(20)14(2)24/h6-7,12,17-21H,5,8-11,13H2,1-4H3/t17-,18-,19+,20-,21+,22-,23?/m1/s1
  • Key:OWNPEOXTHUGQDI-LWAHLCLDSA-N

Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a progestogen of the retroprogesterone group which was developed by Roche but was never marketed. It shows greater potency than dydrogesterone in bioassays.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.